PBM Watch Litigation & Enforcement Tracker
Live snapshot

Pharmacy Benefit Manager Accountability · July 2026

The middlemen are on trial.

A consolidated view of every active federal and state action against the pharmacy benefit managers — Caremark, Express Scripts, OptumRx and the GoodRx pricing alliance. Each status, judge, allegation and filing is tagged with a plain-English explainer. Hover anything.

Last reviewed June 11, 2026  ·  Sources: FTC Legal Library, U.S. District Court (D.R.I.), JPML, NCPA & plaintiff firms.

Recent updates
2+
Major federal proceedings running in parallel
6
PBM & pricing-platform defendants under tracking
40+
Independent-pharmacy plaintiffs consolidated in MDL 3148
$7B
Projected 10-yr patient savings cited in the ESI settlement
Parties
Status
01

Real-time status grid

Where each defendant stands in each proceeding, right now. A cell is a verdict-at-a-glance — hover for the why.

Rows = defendants
Columns = proceedings
Active / Contested Negotiating / Stayed Settled Pending ruling Not named
02

Case dossiers

The full file on each proceeding — court, judge, defendants, the legal theory, the latest docket entries, and who’s saying what.

03

State & legislative front

The courts aren’t the only battlefield. States and Congress are rewriting the rules PBMs operate under.

Executive Summary

The FTC front is settling out — and the private price-fixing war takes center stage.

After two years of pressure, the pharmacy-benefit-manager model is being challenged on every front at once. In February 2026 the FTC won a landmark consent settlement with Express Scripts in the insulin rebating case (Docket 9437), finalized June 10, 2026. That deal cracked the wall — and Caremark and OptumRx followed: both have now reached their own proposed consent agreements, with OptumRx, the last holdout, tentatively settling in June 2026. On June 30, the 8th Circuit dismissed the PBMs’ constitutional countersuit against the FTC by mutual agreement, closing out the last open thread in the federal case.

In parallel, every major PBM faces a private antitrust war: independent pharmacies allege that the GoodRx ISP let competitors fix the prices they pay pharmacies — a textbook Sherman Act §1 claim now consolidated before one judge in Rhode Island.

The throughline: regulators and pharmacies are attacking the same machinery — rebate-driven pricing and DIR-style fee clawbacks — from two directions.

  • i.All three have folded. Express Scripts settled, and Caremark and OptumRx have both reached proposed consent agreements. The FTC insulin case is effectively resolved — and its de-linked, transparent-pricing terms are becoming the template for every PBM contract.
  • ii.The constitutional fight is over. The PBMs’ countersuit against the FTC was dismissed by the 8th Circuit on June 30 — mutually dropped now that all three have settled or proposed settlements.
  • iii.The pharmacy MDL is at its hinge point. A pending motion to dismiss in MDL 3148 will decide whether the price-fixing theory survives to discovery.
  • iv.Watch arbitration. PBM contracts may force some pharmacies out of court — the single biggest threat to the class action.
  • v.For employers: settlements are forcing transparency and de-linked pricing into standard PBM contracts. The next renewal is the moment to demand it.